Article information
Full text is only aviable in PDF
REFERENCES
[1]
P Zimmet, KG Alberti, S Shaw.
Global and social implications of diabetes epidemic.
Nature, 414 (2001), pp. 782-787
[2]
JS Patton, JG Bukar, MA Eldon.
Clinical pharmacokinetics and pharmacodynamics of inhaled insulin.
Clin Pharmacokinet, 43 (2004), pp. 781-801
[3]
TR Strack.
Inhaled human insulin.
Drugs of Today, 42 (2006), pp. 207-221
[5]
T Quattrin, A Bélanger, NJ Bohannon, SL Schwartz, Exubera Phase III Study Group.
Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.
Diabetes Care, 27 (2004), pp. 2622-2627
[6]
JS Skyler, L Jovanovic, S Klioze, J Reis, W Duggan.
Inhaled Human Insulin Type 1 Diabetes Study Group. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes.
Diabetes Care, 30 (2007), pp. 579-585
[7]
J Rosenstock, B Zinman, LJ Murphy, SC Clement, P Moore, CK Bowering, et al.
Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial.
Ann Intern Med, 143 (2005), pp. 549-558
[8]
RA deFronzo, RM Bergenstal, WT Cefalu, J Pullman, S Lerman, BW Bode, et al.
Exubera Phase III Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial.
Diabetes Care, 28 (2005), pp. 1922-1928
[9]
PA Hollander, L Blonde, R Rowe, AE Mehta, JL Milburn, KS Hershon, et al.
Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.
Diabetes Care, 27 (2004), pp. 2356-2362
[10]
C Duna, MP Curran.
Inhaled human insulin (Exubera®). A review of its use in adult patients with diabetes mellitus.
Drugs, 66 (2006), pp. 1013-1032
[11]
RJ Riese, JG Teeter, RD England.
Inhaled insulin does not induce immediate airway responsiveness in patients with type 1 diabetes mellitus.
Eur Respir J, 26 (2005), pp. 582
[12]
M Dreyer.
Exubera® Phase 3 Study Group. Efficacy and 2-year pulmonary safety data of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled with oral monotherapy.
Diabetologia, 47 (2004), pp. A44
[13]
MC Hinojosa Mena-Bernal, E González Sarmiento, J Hinojosa Mena- Bernal.
Estudio epidemiológico de la población diabética ingresada en el Hospital Universitario de Valladolid en el año 1997.
Endocrinol Nutr, 10 (2001), pp. 289-294
[14]
S Kitamura.
Effects of cigarette smoking on metabolic events in the lung.
Environ Health Perspect, 72 (1987), pp. 283-296
[15]
A Himmelmann, J Jendle, A Mellén, AH Petersen, UL Dahl, P Wollmer.
The impact of smoking on inhaled insulin.
Diabetes Care, 26 (2003), pp. 677-682
[16]
RH Becker, S Sha, AD Frick, RJ Fountaine.
The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin.
Diabetes Care, 9 (2006), pp. 277-282
[17]
L Fabbri.
Pulmonary safety of inhaled insulins: a review of the current data.
Curr Med Res Opin, 22 (2006), pp. 21-28
[18]
Exubera®, Pfizer Lab., a division of Pfizer Inc., (2006),
[19]
RR Henry, SR Mudaliar, WC Howland, N Chu, D Kim, B An, et al.
Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects.
Diabetes Care, 26 (2003), pp. 764-769
[20]
R Fountaine, A Milton, G Wei, J Teeter, M Stolar, T Checchio, et al.
Pfizer Global Research and Development. Effects of albuterol and fluticasone on inhaled human insulin (Exubera® (insulin human (rDNA origin) inhalation powder) pharmacokinetics in patients with mild to moderate asthma. Actas de 66th Annual Scientific Sessions of the ADA; 2006, junio 9-13; Washington, American Diabetes Association, (2006),
[21]
K Rave, A de la Peña, FS Tibaldi, L Zhang, B Silverman, M Hausmann, et al.
AIR® inhaled insulin in subjects with chronic obstructive pulmonary disease. Pharmacokinetics, glucodynamics, safety and tolerability.
Diabetes Care, 30 (2007), pp. 1777-1782
[22]
A McElduff, LE Mather, PC Kam, P Clauson.
Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System.
Br J Clin Pharmacol, 60 (2005), pp. 114
[23]
N Freemantle, L Blonde, D Duhot, M Hompesch, R Eggertsen, FD Hobbs, et al.
Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes.
Diabetes Care, 28 (2005), pp. 427-428
[24]
J Rosenstock, JC Cappelleri, B Bolinder, RA Gerber.
Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes.
Diabetes Care, 27 (2004), pp. 1318-1323
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
